Sarepta Therapeutics (LTS:0L35) General and Admin. Expense: $467 Mil (TTM As of Mar. 2026)


LTS:0L35 Sarepta Therapeutics Inc LTS:0L35
51 GF Score
Price $19.09
GF Value $131.71
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics General and Admin. Expense?

Sarepta Therapeutics LTS:0L35 51 General and Admin. Expense is $467 Mil as of Mar. 2026. GuruFocus rates LTS:0L35 with a GF Score™ of 51/100 and a GF Value™ of $131.71 (Possible Value Trap). The stock has 5 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Sarepta Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $109 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $467 Mil.

Sarepta Therapeutics General and Admin. Expense Related Terms

Sarepta Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics General and Admin. Expense Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 282.66 451.42 481.87 557.87 491.72

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.63 137.90 91.89 128.30 108.95
LTS:0L35
51GF Score
Sarepta Therapeutics Inc LTS:0L35
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $467 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $467 Mil mean?
Sarepta Therapeutics (LTS:0L35) has a General and Admin. Expense of $467 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' General and Admin. Expense too high?
Sarepta Therapeutics' current General and Admin. Expense is $467 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' General and Admin. Expense compare to ZYME and BCAX?
Sarepta Therapeutics' General and Admin. Expense of $467 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current General and Admin. Expense is $467 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $131.71, compared to a current price of $19.09 — trading 85.5% below its estimated fair value. The current General and Admin. Expense is $467 Mil. Sarepta Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current General and Admin. Expense is $467 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $19.09 is trading 85.5% below its estimated GF Value™ of $131.71. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0L35:

  • General and Admin. Expense: $467 Mil
  • GF Value™: $131.71 vs. price of $19.09 (85.5% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
51GF Score

Get the complete analysis for LTS:0L35

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.09
Price
$131.71
GF Value